The Filing Desk

Firefly Neuroscience

AIFF · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

AIFF · Last close · November 19, 2026
$0.80
Value Firefly Neuroscience yourself

Firefly Neuroscience's revenue rose 957.4% to $1 million in fiscal 2025. Its operating margin was −775.5%, up from −9,309.3% a year earlier. The diluted share count rose 90.1%.

FIREFLY NEUROSCIENCE, INC. Latest fiscal year ended December 31, 2025 10-K filed March 31, 2026 · 0001437749-26-010500 Updated
Revenue
$1M
957.4%
Operating margin
−775.5%
8533.8 pts
Net income
−$20M
 
Free cash flow
—
 
Return on capital
−411.7%
 
Market cap
$17M
Nov 19 close
P/E
—
 

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Interest coverage for fiscal 2025 is blank: the 10-K's structured data has no interest expense for that year.

Charts show fiscal years, from the 10-K filings.

What Firefly Neuroscience does

Firefly Neuroscience makes a system that measures the brain's electrical activity and turns it into reports for doctors. Its Evoke System, cleared by the US Food and Drug Administration, records an EEG (electroencephalogram, a reading of brain waves) and ERPs (the brain's responses to set tasks) in a clinic. Firefly's cloud software then compares each patient's results with a reference group and sends the doctor a structured report. Its customers are mainly neurology and psychiatry clinics in the United States, and the system was in use at more than 85 sites at the end of 2025.

Clinics pay a monthly subscription that covers the hardware, a set number of assessments and the reports, with extra scans billed per scan. Firefly says it faces competition from other technologies, and that rivals may include large companies with more resources.

The company has a database of more than 191,000 EEG and ERP records from more than 100,000 patients, covering over 12 neurological and psychiatric conditions. It bought Evoke Neuroscience, the maker of the Evoke System, in April 2025. It has 17 full-time employees, some of them in Israel.

Its biggest risks, as it describes them

  • It faces liquidity problems that raise substantial doubt about its ability to continue as a going concern.
  • It may fail to get more clinics to adopt its system, or to get doctors to accept the clinical data behind it.
  • Its sales may depend on patients and clinics getting paid back by insurers and other payers.
  • Strict FDA rules: changes to its devices or new products may need new clearances that it might not get.
  • War and unrest involving Israel and Iran could disrupt its staff and operations in Israel.
From Firefly Neuroscience's annual report on Form 10-K, filed March 31, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2017 to 2020, earnings per share grew 14.5% a year and net income 26.0% a year, as new shares raised the share count by 3% and diluted each share's earnings. Firefly Neuroscience then lost money in fiscal 2021, 2022, 2023, 2024 and 2025.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments51123
Debt incl. finance leases00010
Net debt (negative means net cash)−5−1−1−1−3
Net debt to EBITDA—————
Debt to equity0.0x———0.0x
Interest coverage−70.4x−66.4x−29.8x−914.0x—
Current ratio3.5x0.7x0.9x0.5x1.4x
Quick ratio3.5x0.7x0.9x0.5x1.4x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Firefly Neuroscience's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Firefly Neuroscience reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 91 of 94 of 9
Rule of 40−532.0%——
Altman Z''−103.06−79.81−36.83
Accruals ratio−8.1%−118.9%−155.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailPass
Current ratio rosePassFailPass
Share count didn't riseFailFailFail
Gross margin rosePassFailFail
Revenue rose relative to assetsFailFailPass
F-score4 of 91 of 94 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Firefly Neuroscience side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Firefly NeuroscienceFY25957.4%−775.5%—−411.7%—4
ZhongchaoFY25−28.3%−54.4%6.1%———Compare
BullFrog AIFY25—−5,652.4%————Compare
Healthcare TriangleFY2518.8%−70.5%−119.0%———Compare
SOPHiA GENETICSFY2518.6%−91.8%−47.2%−207.1%—2Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue711910141512001
Revenue growth8.3%58.1%−16.0%13.8%36.8%8.1%−20.0%−95.9%−78.3%957.4%
Gross profit2221243301
Research and development———————122
Operating income−10−0−10−3−5−3−10−9
Net income−10−0−10−1−18−3−10−20
Diluted EPS (US$)−0.050.020.00−0.060.03−0.09————
Diluted shares (millions)11121111121323612
Cash flow
Cash from operations−01−1−10−1−6−2−6−8
Capital expenditure00000000——
Free cash flow−01−1−10−1−7−2——
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation0000021031
Balance sheet at fiscal year end
Cash and short-term investments2321251123
Debt incl. finance leases————000010
Total assets443242383510
Total liabilities2211264253
Shareholders' equity2221217−20−08
Margins and ratios
Gross margin27.1%22.7%24.0%13.8%15.9%24.1%23.8%525.0%100.0%56.5%
Operating margin−8.4%2.2%−0.7%−7.2%3.0%−17.5%−45.1%−618.1%−9,309.3%−775.5%
Net margin−8.2%2.3%−0.6%−7.1%3.0%−7.5%−147.7%−522.7%−9,685.2%−1,741.0%
Free cash flow margin−4.0%7.8%−8.6%−9.1%2.6%−5.3%−54.5%−436.1%——
Rule of 40 (growth + FCF margin)4.3%66.0%−24.6%4.7%39.4%2.8%−74.5%−532.0%——
Return on capital—————−32.6%−89.6%——−411.7%
Return on equity−29.1%14.0%−2.7%−47.3%29.8%−11.9%−233.4%——−547.6%
Return on assets−14.1%6.6%−1.5%−26.6%13.4%−8.3%−113.3%−49.0%−288.9%−263.7%
Net debt to EBITDA————−3.3x—————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Firefly Neuroscience's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Firefly Neuroscience.